Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Synlogic Inc (SYBX)

Synlogic Inc (SYBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Synlogic Inc P.O. Box 30 Winchester MA 01890 USA

www.synlogictx.com Employees: 6 P: 617-401-9975

Description:

Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 17,512
Enterprise Value, $K -6,448
Shares Outstanding, K 11,696
Annual Sales, $ 3,370 K
Annual Net Income, $ -57,280 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ 2,010 K
EBIT, $ -61,690 K
EBITDA, $ -60,550 K
60-Month Beta 0.80
% of Insider Shareholders 3.02%
% of Institutional Shareholders 63.40%
Float, K 11,343
% Float 96.98%
Short Volume Ratio 0.73

Growth:

1-Year Return -64.18%
3-Year Return -95.13%
5-Year Return -96.65%
5-Year Revenue Growth 33.73%
5-Year Earnings Growth 71.06%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 11/12/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -6.72
EPS Growth vs. Prev Qtr -106.25%
EPS Growth vs. Prev Year 99.61%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 09/28/23

SYBX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -207.84%
Return-on-Assets % -114.81%
Profit Margin % -1,699.70%
Debt/Equity 0.00
Price/Sales 6.55
Price/Cash Flow N/A
Price/Book 1.34
Book Value/Share 1.36
Interest Coverage -2.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar